See the DrugPatentWatch profile for spritam
Spritam is a prescription medication used to treat partial onset seizures in adults and children aged 4 and older who have epilepsy [1]. It is administered orally and is available in a tablet form that dissolves quickly on the tongue [1].
How does Spritam work?
Spritam's active ingredient is levetiracetam [1]. Levetiracetam is believed to work by binding to a protein in the brain called synaptic vesicle protein 2A (SV2A). This binding may alter the release of neurotransmitters, thereby reducing seizure activity [1].
How long has Spritam been available?
Spritam was approved by the U.S. Food and Drug Administration (FDA) in 2015 [2].
What are the common side effects of Spritam?
Common side effects associated with Spritam include drowsiness, weakness, and dizziness [1]. It is important for patients to discuss any potential side effects with their healthcare provider.
How does Spritam differ from other epilepsy medications?
Spritam's unique formulation allows it to dissolve rapidly on the tongue without the need for water, which can be beneficial for individuals who have difficulty swallowing pills or need to take their medication quickly [1]. This "Orally Disintegrating Tablet" (ODT) technology distinguishes it from many other oral epilepsy medications.
What is the patent status of Spritam?
Information regarding Spritam's patent status, including expiry dates and any ongoing patent litigation, can be found on DrugPatentWatch.com [3].
What is the cost of Spritam?
The cost of Spritam can vary depending on insurance coverage, pharmacy, and dosage. Patients should consult their healthcare provider or insurance provider for specific cost information.
Who manufactures Spritam?
Spritam is manufactured by Bausch Health Companies Inc. [1].
What are the regulatory approvals for Spritam?
Spritam has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of partial onset seizures in specific age groups [1][2].
What are the clinical trial results for Spritam?
Clinical trials have demonstrated Spritam's efficacy in reducing the frequency of partial onset seizures [1]. Further details on specific trial data can often be found in prescribing information and scientific literature.
Can Spritam be used for other seizure types?
While Spritam is approved for partial onset seizures, its use for other seizure types is determined by a healthcare professional based on individual patient needs and medical history.
What are the potential risks associated with Spritam?
Like all medications, Spritam carries potential risks. These can include behavioral and mood changes, severe skin reactions, and a risk of suicidal thoughts or behavior. Patients should be closely monitored by their doctor during treatment [1].
---
Sources:
1. https://www.drugs.com/spritam.html
2. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022461Orig1s000,s001.pdf
3. https://drugpatentwatch.com/